Ten years ago, a consensus report on the optimization of tacrolimus was published in this
journal. In 2017, the Immunosuppressive Drugs Scientific Committee of the International …

Cytochromes P450 (CYP) are a major source of variability in drug pharmacokinetics and
response. Of 57 putatively functional human CYPs only about a dozen enzymes, belonging …

Tacrolimus is the mainstay immunosuppressant drug used after solid organ and
hematopoietic stem cell transplantation. Individuals who express CYP3A5 (extensive and …

Tacrolimus (FK506) and cyclosporine (cyclosporin A, CsA) are cornerstone
immunosuppressive agents administered to solid organ transplant recipients to prevent and …

The calcineurin inhibitor tacrolimus is the backbone of immunosuppressive drug therapy
after solid organ transplantation. Tacrolimus is effective in preventing acute rejection but has …

Retrospective studies have demonstrated that patients who are expressors of cytochrome
P4503A5 (CYP3A5) require a higher tacrolimus dose to achieve a therapeutic trough …

The calcineurin‐inhibitor tacrolimus (Tac) provides an acceptable balance between
prevention of allograft rejection and drug‐related adverse effects, making it the standard of …

Tacrolimus (Tac) is widely used for the prevention of rejection after solid organ
transplantation. Finding the optimal balance between effective Tac concentrations and …

Many studies have attempted to explain the interindividual variability observed in drug
metabolism by assessing the impact of SNPs in genes implicated in drug absorption …

ABSTRACT Introduction: Tacrolimus (Tac) is the cornerstone of immunosuppressive therapy
after solid organ transplantation and will probably remain so. Excluding belatacept, no new …